Medexus Pharmaceuticals Inc. (TSE:MDP - Get Free Report) shares traded down 13.2% on Thursday . The company traded as low as C$3.25 and last traded at C$3.29. 114,178 shares changed hands during trading, a decline of 36% from the average session volume of 177,975 shares. The stock had previously closed at C$3.79.
Wall Street Analyst Weigh In
A number of research firms recently commented on MDP. Alliance Global Partners upgraded Medexus Pharmaceuticals to a "strong-buy" rating in a report on Monday, December 23rd. Ventum Financial raised their price target on shares of Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the company a "buy" rating in a report on Thursday, January 30th. Stifel Canada cut shares of Medexus Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Thursday. Raymond James upgraded Medexus Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and set a C$4.00 target price on the stock in a report on Wednesday, January 8th. Finally, Leede Financial upgraded Medexus Pharmaceuticals from a "moderate buy" rating to a "strong-buy" rating in a research note on Wednesday, January 22nd. Two analysts have rated the stock with a hold rating, one has issued a buy rating and four have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of C$5.49.
Check Out Our Latest Analysis on Medexus Pharmaceuticals
Medexus Pharmaceuticals Stock Performance
The company's 50 day moving average is C$3.54 and its 200 day moving average is C$2.83. The stock has a market capitalization of C$76.78 million, a price-to-earnings ratio of 62.60 and a beta of 1.96.
Medexus Pharmaceuticals Company Profile
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Featured Articles
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
